184 related articles for article (PubMed ID: 34213600)
1. A systematic review of neurocognitive dysfunction with overactive bladder medications.
Duong V; Iwamoto A; Pennycuff J; Kudish B; Iglesia C
Int Urogynecol J; 2021 Oct; 32(10):2693-2702. PubMed ID: 34213600
[TBL] [Abstract][Full Text] [Related]
2. Receipt of Overactive Bladder Drugs and Incident Dementia: A Population-based Case-control Study.
Matta R; Gomes T; Juurlink D; Jarvi K; Herschorn S; Nam RK
Eur Urol Focus; 2022 Sep; 8(5):1433-1440. PubMed ID: 34742663
[TBL] [Abstract][Full Text] [Related]
3. Effect of Antimuscarinic Drugs on Cognitive Functions in the Management of Overactive Bladder in Elderly.
Rangganata E; Widia F; Rahardjo HE
Acta Med Indones; 2020 Jul; 52(3):255-263. PubMed ID: 33020336
[TBL] [Abstract][Full Text] [Related]
4. A comprehensive non-clinical evaluation of the CNS penetration potential of antimuscarinic agents for the treatment of overactive bladder.
Callegari E; Malhotra B; Bungay PJ; Webster R; Fenner KS; Kempshall S; LaPerle JL; Michel MC; Kay GG
Br J Clin Pharmacol; 2011 Aug; 72(2):235-46. PubMed ID: 21392072
[TBL] [Abstract][Full Text] [Related]
5. Which anticholinergic drug for overactive bladder symptoms in adults.
Madhuvrata P; Cody JD; Ellis G; Herbison GP; Hay-Smith EJ
Cochrane Database Syst Rev; 2012 Jan; 1():CD005429. PubMed ID: 22258963
[TBL] [Abstract][Full Text] [Related]
6. Which antimuscarinic agents used in the treatment of overactive bladder increase heart rate? a prospective randomized clinical trial.
Cetinel B; Onal B; Gultekin MH; Guzelsoy M; Turegun FA; Dincer M
Int Urol Nephrol; 2019 Mar; 51(3):417-424. PubMed ID: 30725387
[TBL] [Abstract][Full Text] [Related]
7. Comparative assessment of efficacy and safety of approved oral therapies for overactive bladder: a systematic review and network meta-analysis.
He W; Huang G; Cui W; Tian Y; Sun Q; Zhao X; Zhao Y; Li D; Liu X
Int Braz J Urol; 2023; 49(5):535-563. PubMed ID: 37506033
[TBL] [Abstract][Full Text] [Related]
8. Systematic review and meta-analysis: do clinical trials testing antimuscarinic agents for overactive bladder adequately measure central nervous system adverse events?
Paquette A; Gou P; Tannenbaum C
J Am Geriatr Soc; 2011 Jul; 59(7):1332-9. PubMed ID: 21718264
[TBL] [Abstract][Full Text] [Related]
9. Comparative efficacy and tolerability of solifenacin 5 mg/day versus other oral antimuscarinic agents in overactive bladder: A systematic literature review and network meta-analysis.
Nazir J; Kelleher C; Aballéa S; Maman K; Hakimi Z; Mankowski C; Odeyemi I
Neurourol Urodyn; 2018 Mar; 37(3):986-996. PubMed ID: 29140559
[TBL] [Abstract][Full Text] [Related]
10. Long-term safety and efficacy of antimuscarinic add-on therapy in patients with overactive bladder who had a suboptimal response to mirabegron monotherapy: A multicenter, randomized study in Japan (MILAI II study).
Yamaguchi O; Kakizaki H; Homma Y; Igawa Y; Takeda M; Nishizawa O; Gotoh M; Yoshida M; Yokoyama O; Seki N; Okitsu A; Hamada T; Kobayashi A; Kuroishi K
Int J Urol; 2019 Mar; 26(3):342-352. PubMed ID: 30548692
[TBL] [Abstract][Full Text] [Related]
11. Treatments for overactive bladder: focus on pharmacotherapy.
Geoffrion R;
J Obstet Gynaecol Can; 2012 Nov; 34(11):1092-1101. PubMed ID: 23231848
[TBL] [Abstract][Full Text] [Related]
12. Comparisons of the therapeutic safety of seven oral antimuscarinic drugs in patients with overactive bladder: a network meta-analysis.
Yang N; Wu Q; Xu F; Zhang X
J Int Med Res; 2021 Sep; 49(9):3000605211042994. PubMed ID: 34510960
[TBL] [Abstract][Full Text] [Related]
13. Persistence with prescribed antimuscarinic therapy for overactive bladder: a UK experience.
Wagg A; Compion G; Fahey A; Siddiqui E
BJU Int; 2012 Dec; 110(11):1767-74. PubMed ID: 22409769
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics and toxicity of antimuscarinic drugs for overactive bladder treatment in females.
Leone Roberti Maggiore U; Salvatore S; Alessandri F; Remorgida V; Origoni M; Candiani M; Venturini PL; Ferrero S
Expert Opin Drug Metab Toxicol; 2012 Nov; 8(11):1387-408. PubMed ID: 22871042
[TBL] [Abstract][Full Text] [Related]
15. The cognitive effect of anticholinergics for patients with overactive bladder.
Welk B; Richardson K; Panicker JN
Nat Rev Urol; 2021 Nov; 18(11):686-700. PubMed ID: 34429535
[TBL] [Abstract][Full Text] [Related]
16. Preserving cognitive function for patients with overactive bladder: evidence for a differential effect with darifenacin.
Kay GG; Ebinger U
Int J Clin Pract; 2008 Nov; 62(11):1792-800. PubMed ID: 18699842
[TBL] [Abstract][Full Text] [Related]
17. Choosing the Most Efficacious and Safe Oral Treatment for Idiopathic Overactive Bladder: A Systematic Review and Network Meta-analysis.
Mostafaei H; Salehi-Pourmehr H; Jilch S; Carlin GL; Mori K; Quhal F; Pradere B; Grossmann NC; Laukhtina E; Schuettfort VM; Aydh A; Sari Motlagh R; König F; Roehrborn CG; Katayama S; Rajwa P; Hajebrahimi S; Shariat SF
Eur Urol Focus; 2022 Jul; 8(4):1072-1089. PubMed ID: 34563481
[TBL] [Abstract][Full Text] [Related]
18. Antimuscarinic drugs: review of the cognitive impact when used to treat overactive bladder in elderly patients.
Pagoria D; O'Connor RC; Guralnick ML
Curr Urol Rep; 2011 Oct; 12(5):351-7. PubMed ID: 21607875
[TBL] [Abstract][Full Text] [Related]
19. Oral pharmacotherapy for overactive bladder in older patients: mirabegron as a potential alternative to antimuscarinics.
Wagg A; Nitti VW; Kelleher C; Castro-Diaz D; Siddiqui E; Berner T
Curr Med Res Opin; 2016; 32(4):621-38. PubMed ID: 26828974
[TBL] [Abstract][Full Text] [Related]
20. Pharmacologic management of overactive bladder.
Lam S; Hilas O
Clin Interv Aging; 2007; 2(3):337-45. PubMed ID: 18044184
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
